Glaucoma News and Research RSS Feed - Glaucoma News and Research

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.
NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser. [More]
Glaucoma drug may help reverse obesity-related vision loss in women

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health. [More]

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD). [More]

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma. [More]

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). [More]
Research report on global ophthalmology devices market

Research report on global ophthalmology devices market

The "Ophthalmology Devices Market (Optical Coherence Tomography (OCT) Scanner, Fundus Camera, Tonometer, Pachymeter, Perimeter, Slit Lamp, Excimer, YAG Laser, Femtosecond Laser, IOL, Contact Lens) - Competitive Landscape & Global Forecasts to 2018", published by MarketsandMarkets, the ophthalmology devices market inclusive of diagnostic, monitoring and surgical devices is expected to grow at a CAGR of 6.8% to reach $9,466.7 Million by 2018. [More]

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days. [More]
Perrigo launches methazolamide tablets

Perrigo launches methazolamide tablets

Perrigo Company today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year. [More]
Research explores new diagnostic strategies to detect glaucoma

Research explores new diagnostic strategies to detect glaucoma

Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it. [More]
ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. [More]

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). [More]
New corneal layer important for intraocular pressure maintenance

New corneal layer important for intraocular pressure maintenance

UK researchers have found that a newly discovered layer of the human eye is an important part of the structural tissue that helps to maintain intraocular pressure and thus may play a role in the development of glaucoma. [More]

UAB launches pilot program to detect earlier stages of glaucoma

Glaucoma is a silent disease. It does not hurt, symptoms are slow to develop, and most people do not notice any loss of vision until it is too late. A project by ophthalmologists at the University of Alabama at Birmingham will examine whether a partnership with community-based optometrists will improve detection and treatment of glaucoma, especially for high-risk populations. [More]
Jackson Laboratory Assistant Professor wins 2013 Lewis Rudin Glaucoma Prize from NYAM

Jackson Laboratory Assistant Professor wins 2013 Lewis Rudin Glaucoma Prize from NYAM

Jackson Laboratory Assistant Professor Gareth Howell, Ph.D., is one of two winners of the 2013 Lewis Rudin Glaucoma Prize from The New York Academy of Medicine. [More]
IIN collaborates with Nanyang Technological University to establish Nanomedicine

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Northwestern University's International Institute for Nanotechnology (IIN) is collaborating with Nanyang Technological University (NTU), Singapore, to establish the NTU-Northwestern Institute for Nanomedicine. [More]
Study reveals that color vision abnormalities increase with age

Study reveals that color vision abnormalities increase with age

​Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry. [More]

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

​By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness. [More]

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, performed the first procedures using the ReSure Sealant on his cataract patients in Durham, North Carolina. The ReSure Sealant is the first FDA-approved sealant for ophthalmic use to seal incisions following cataract surgery. [More]

Dua's Layer in the human cornea may be linked to glaucoma

A new layer in the human cornea - discovered by researchers at The University of Nottingham last year - plays a vital role in the structure of the tissue that controls the flow of fluid from the eye, research has shown. [More]
Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. [More]